Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study

  28 August 2020

Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. The authors determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19.

The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.

Author(s): Valerie M Vaughn, MD, MSc, Tejal Gandhi, MD, Lindsay A Petty, MD, Payal K Patel, MD, MPH, Hallie C Prescott, MD, MSc, Anurag N Malani, MD, David Ratz, MS, Elizabeth McLaughlin, MS, RN, Vineet Chopra, MD, MSc, Scott A Flanders, MD
Effective Surveillance   Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!